Agile Therapeutics AGRX reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM.
Here's what investors need to know about the announcement.
Earnings
Agile Therapeutics missed estimated earnings by -59.0%, reporting an EPS of $-1.46 versus an estimate of $-0.92.
Revenue was down $381 thousand from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.37 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Agile Therapeutics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -1.84 | -3.48 | -7.50 | -11.5 |
EPS Actual | -1.47 | -3.10 | -7.76 | -9 |
Revenue Estimate | 5.27M | 4.68M | 3.40M | 3.08M |
Revenue Actual | 6.66M | 5.50M | 3.81M | 4.00M |
To track all earnings releases for Agile Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.